A similar outcome was obtained when eIF4A1 was pharmacologically targeted with the natural, small molecule inhibitor, Rocaglamide A. This was the first report that highlights that targeting of eIF4A could downregulate all three pluripotency transcription factors that regulate BC stemness.9 This evidence concerns the gene EIF4A1 and breast cancer.